Clinical Trial

Mild ANH on Pre-bypass Coagulation Function During Cardiac Surgery

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated October 31, 2024 (before its estimated March 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The impact of acute normovolemic hemodilution (ANH) using hydroxyethyl starch before initiating cardiopulmonary bypass (CPB) on whole blood viscoelastic profile after CPB has not been well established. Patients undergoing cardiac surgery employing moderate hypothermic CPB are randomly allocated into one of two groups: in Group-ANH, ANH is applied by using a balanced hydroxyethyl starch (HES 130/0.6); and in Group-C, ANH is not applied. After weaning from CPB, intergroup differences of INTEM, EXTEM, FIBTEM, and APTEM profiles are analyzed. As a primary outcome, the inter-group differences between maximal clot firmness of EXTEM will be determined at 10 min after ANH in Group-ANH and that at control.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-10-27.
Trial Details
NCT Number NCT06664320
Lead Sponsor Konkuk University Medical Center
Conditions Mitral Regurgitation, Mitral Stenosis, Tricuspid Regurgitation
Enrollment 70 participants
Start Date 2024-10-28
Primary Completion 2025-03-30 (estimated)
Study Completion 2025-04-30 (estimated)
Updated on ClinicalTrials.gov 2024-10-31